Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc. and Exelixis, Inc.

Community Practice Connections: How Will You Sequence Now? Personalizing Care Along the RCC Treatment Continuum When There are Many Options

Release Date: March 31, 2020
Expiration Date: March 31, 2021

Activity Overview

The availability of new systemic immune checkpoint inhibitor (ICI) and VEGF tyrosine kinase inhibitor (TKI) agents and combination regimens (eg, ICI-ICI, ICI-TKI) has expanded the lines of therapy available to your patients with metastatic renal cell carcinoma (mRCC). Consequently, new clinical dilemmas regarding rational treatment planning and optimized sequencing of new and older standards of care have arisen.

This multimedia, educational activity includes a review of the most recent and practically relevant data and best practices, along with conversations between the faculty regarding clinical uncertainties faced in daily practice. For example: What factors should influence your frontline and subsequent-line treatment selection? Is there still a role for IMDC risk stratification? How should you monitor and manage toxicities associated with newer regimens? What are the evolving roles of local therapy in the modern era? Are additional practice changes anticipated to arise in 2020?

Benefits of Participating

  • Hear from the experts on how they approach RCC cases you typically encounter in your clinical practice
  • Improve your ability to optimize clinical decision-making for your patients with advanced/metastatic RCC
  • Compare your practices with those of the experts and your colleagues

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc. and Exelixis, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the biologic rationale for the use of targeted agents and immunotherapies, as single agents and in combination, to treat renal cell carcinoma (RCC).
  • Analyze practice-changing and emerging data from clinical trials of systemic therapies for use across multiple lines of therapy for advanced RCC.
  • Integrate knowledge of the safety profiles of systemic therapies with best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC.
  • Consider the efficacy and safety of single-agent and combination systemic therapies, as well as patient and disease characteristics and patient preferences, as part of shared decision-making for patients with metastatic RCC.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Robert A. Figlin, MD, FACP
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Associate Director, Oncology Service Line, Cedars-Sinai Cancer
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: no relevant financial relationships with commercial interests.

Laurence Albiges, MD, PhD
Laurence Albiges, MD, PhD
Medical Oncologist
Gustave Roussy Institute
Villejuif, France

Disclosures: Grant/Research Support: BMS; Consultant: Amgen, Astellas Pharma, AstraZenenca, BMS, Exelixis, Ipsen, Merck & Co., MSD, Novartis, Pfizer, Roche.

Toni K. Choueiri, MD
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Bayer, Bristol-Myers Squibb/ER Squibb and sons LLC, Calithera Biosciences, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, Foundation Medicine Inc, Exelixis, F. Hoffmann-La Roche, GlaxoSmithKline, Genentech, Ipsen, Eli Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products Limited , Sanofi/Aventis, Takeda, Tracon Pharmaceuticals; Consultant: Analysis Group, AstraZeneca, Alexion, Bayer, Bristol-Myers Squibb/ER Squibb and sons LLC, Cerulean, Corvus, Eisai, Foundation Medicine Inc, EMD Serono, Exelixis, GlaxoSmithKline, Genentech, Heron Therapeutics, Ipsen, Eli Lilly, Merck, NCCN, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Sanofi/Aventis, Up-to-Date; Other: Honoraria: Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Corvus, Eisai, Foundation Medicine Inc, EMD Serono, Exelixis, F. Hoffmann-La Roche, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Eli Lilly, Merck, NCCN, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products Limited, Up-to-Date, Sanofi/Aventis.

Sumanta K. Pal, MD
Sumanta K. Pal, MD
Medical Oncologist
City of Hope
Los Angeles, CA

Disclosures: Consultant: Astellas, Aveo, Bristol-Myers Squibb, Eisal, Exelixis, Genentech, Ipsen, Novartis, Pfizer, Roche.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
252627282930
Filter By